Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05551052 · ClinicalTrials.gov registry record
CRC Detection Reliable Assessment With Blood
A clinical trial of Colorectal Cancer and Colon Cancer, sponsored by New Day Diagnostics.
- Active
- Registry status
- 196
- Enrollment target
- 3
- Study locations
NCT05551052: Active study of Colorectal Cancer and Colon Cancer, sponsored by New Day Diagnostics.
NCT05551052 is a study of Colorectal Cancer and Colon Cancer that is active but no longer recruiting, run by New Day Diagnostics. The registered enrollment target is 196 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05551052, a study of Colorectal Cancer and Colon Cancer, is active but no longer recruiting, sponsored by New Day Diagnostics.
- ACTIVE NOT RECRUITING
- Registry status
- 196 participants
- Enrollment target
- 3
- Study locations
Study Summary
The CRC DRAW study will assess the sensitivity and specificity of the blood-based, Next-Gen CRC Screening Test for the detection of CRC.
Primary Outcome
Clinical Performance
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Next-Gen CRC Screening Test
Study Locations (3)
California
- Gastro SB - Chula Vista
- SDG Clinical Research - San Diego
- Medical Associates Research Group - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2022-09-08 |
| Est. Completion | 2027-12-31 |
What the registry record for NCT05551052 still lists
NCT05551052 is an observational study that tracks outcomes without assigning an intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (87% lower).
The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Next-Gen CRC Screening Test is the first listed.
NCT05551052 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05551052 about?
NCT05551052 is a clinical study titled "CRC Detection Reliable Assessment With Blood". The CRC DRAW study will assess the sensitivity and specificity of the blood-based, Next-Gen CRC Screening Test for the detection of CRC.
What is the current status of trial NCT05551052?
This trial is currently active not recruiting. The enrollment target is 196 participants. The study started on 2022-09-08. Estimated completion is 2027-12-31.
What conditions does trial NCT05551052 study?
This clinical trial studies the following conditions: Colorectal Cancer, Colon Cancer, Rectal Cancer, Adenoma, Colon Polyp.
What interventions are being tested in trial NCT05551052?
The interventions under investigation include: Next-Gen CRC Screening Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05551052?
This trial is sponsored by New Day Diagnostics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05551052 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05551052's enrollment target sits among peer trials
196 153rd of 381 higher than 229 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02822768 · 196 participants · NA
Packing Versus no Packing for Cutaneous Abscess
- NCT04250259 · 196 participants · Phase 2
SAMe Trial for Patients With Alcoholic Cirrhosis
- NCT05142592 · 196 participants · Phase 1
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
- NCT05317832 · 196 participants · Phase 2
Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI